Rosalyn Irby

Associate Professor of Cancer Research

Rosalyn Irby

Huck Affiliations

Publication Tags

These publication tags are generated from the output of this researcher. Click any tag below to view other Huck researchers working on the same topic.

Neoplasms Fluorouracil Colonic Neoplasms Prostate Apoptosis Response 4 Protein Apoptosis Therapeutics Cells Proteins Cetuximab Protein Phosphorylation Protein Tyrosine Kinases Tumor Suppressor Protein Colorectal Neoplasms Apoptosis Regulatory Proteins Isatin Pancreatic Neoplasms Resistance Tubulin Modulators Protein Kinase B Inhibitor Antineoplastic Agent Cell Line Neoplasm Cells Genes Colon

Most Recent Publications

TRIM21 is a novel regulator of Par-4 in colon and pancreatic cancer cells

Jeffrey Q. Nguyen, Rosalyn B. Irby, 2017, Cancer Biology and Therapy on p. 16-25

Intra-cellular tyrosine kinase

Rosalyn Irby, Timothy J. Yeatman, 2015, on p. 231-242

The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer

Joshua E. Allen, Jean Nicolas Gallant, David T. Dicker, Shantu Amin, Rosalyn B. Irby, Arun K. Sharma, Wafik S. El-Deiry, 2013, PLoS One

Par-4 as a potential target for cancer therapy

Rosalyn B. Irby, Christina Lb Kline, 2013, Expert Opinion on Therapeutic Targets on p. 77-87

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study

Susan Bell Nyland, Daniel J. Krissinger, Michael J. Clemente, Rosalyn B. Irby, Kendall Thomas Baab, Nancy Ruth Jarbadan, Lubomir Sokol, Eric Schaefer, Jason Liao, David Cuthbertson, Pearlie Epling-Burnette, Ronald Paquette, Alan F. List, Jaroslaw P. Maciejewski, Thomas P. Loughran, 2012, Leukemia Research on p. 581-587

The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU

Christina Leah B. Kline, Rosalyn B. Irby, 2011, Apoptosis : an international journal on programmed cell death on p. 1285-1294

Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway

Krishne Gowda, A. S. Prakasha Gowda, Hephzibah Rani S. Tagaram, Kevin F.Staveley O. Carroll, Rosalyn Irby, Arun Sharma, Shantu Amin, 2011, Bioorganic and Medicinal Chemistry on p. 6006-6014

The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model

Arun K. Sharma, Christina L. Kline, Arthur Berg, Shantu Amin, Rosalyn B. Irby, 2011, Clinical Cancer Research on p. 4474-4483

Tyrosine kinase update: Role and response in cancer therapy

Rosalyn B. Irby, Yixing Jiang, 2011, Current Cancer Therapy Reviews on p. 155-166

Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NFκB and microRNA network

Bi-Dar Wang, Christina Kline, Danielle Pastor, Thomas Olson, Bryan Frank, Truong Luu, Arun Sharma, G Robertson, Matthew Weirauch, Steven Patierno, Joshua Stuart, R Irby, Norman Lee, 2010, Molecular Cancer

Most-Cited Papers

TRIM21 is a novel regulator of Par-4 in colon and pancreatic cancer cells

Jeffrey Q. Nguyen, Rosalyn B. Irby, 2017, Cancer Biology and Therapy on p. 16-25

The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer

Joshua E. Allen, Jean Nicolas Gallant, David T. Dicker, Shantu Amin, Rosalyn B. Irby, Arun K. Sharma, Wafik S. El-Deiry, 2013, PLoS One

Par-4 as a potential target for cancer therapy

Rosalyn B. Irby, Christina Lb Kline, 2013, Expert Opinion on Therapeutic Targets on p. 77-87

Intra-cellular tyrosine kinase

Rosalyn Irby, Timothy J. Yeatman, 2015, on p. 231-242